{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:36:53Z","timestamp":1740123413556,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T00:00:00Z","timestamp":1480377600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s10822-016-9994-0","type":"journal-article","created":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T04:08:18Z","timestamp":1480392498000},"page":"293-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Modeling & Informatics at Vertex Pharmaceuticals Incorporated: our philosophy for sustained impact"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-965X","authenticated-orcid":false,"given":"Georgia","family":"McGaughey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Patrick Walters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,29]]},"reference":[{"key":"9994_CR1","volume-title":"The billion dollar molecule: one company\u2019s quest for the perfect drug","author":"B Werth","year":"1995","unstructured":"Werth B (1995) The billion dollar molecule: one company\u2019s quest for the perfect drug, revised edn. Simon & Schuster, New York","edition":"revised"},{"key":"9994_CR2","volume-title":"The antidote: inside the world of new pharma","author":"B Werth","year":"2014","unstructured":"Werth B (2014) The antidote: inside the world of new pharma, reprint edn. Simon & Schuster, New York","edition":"reprint"},{"issue":"2014","key":"9994_CR3","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","volume":"57","author":"M Clark","year":"2014","unstructured":"Clark M, Ledeboer M, Davies I, Byrn R, Jones S, Perola E, Tsai A, Jacobs M, Nti-Addae K, Bandarage U, Boyd M, Bethiel R, Court J, Deng H, Duffy J, Dorsch W, Farmer L, Gao H, Gu W, Jackson K, Jacobs D, Kennedy J, Ledford B, Liang J, Maltais F, Murcko M, Wang T, Wannamaker M, Bennett H, Leeman J, McNeil C, Taylor W, Memmott C, Jiang M, Rijnbrand R, Bral C, Germann U, Nezami A, Zhang Y, Salituro FG, Bennani YL, Charifson P (2014) Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2\u201d. J Med Chem 57(2014):6668\u20136678","journal-title":"J Med Chem"},{"key":"9994_CR4","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1021\/jm800318d","volume":"51","author":"PS Charifson","year":"2008","unstructured":"Charifson PS, Grillot A-L, Grossman TH, Parsons JD, Badia M, Bellon S, Deininger DD, Drumm JE, Gross CH, LeTiran A, Liao Y, Mani N, Nicolau DP, Perola E, Ronkin S, Shannon D, Swenson LL, Tang Q, Tessier PR, Tian SK, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D (2008) Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem 51:5243\u20135263","journal-title":"J Med Chem"},{"key":"9994_CR5","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.bmcl.2014.03.022","volume":"24","author":"E Perola","year":"2014","unstructured":"Perola E, Stamos D, Grillot AL, Ronkin S, Wang T, LeTiran A, Tang Q, Deininger DD, Liao Y, Tian SK, Drumm JE, Nicolau DP, Tessier PR, Mani N, Grossman TH, Charifson PS (2014) Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy Bioorg. Med Chem Lett 24:2177\u20132181","journal-title":"Med Chem Lett"},{"key":"9994_CR6","first-page":"1027","volume":"52","author":"E Perola","year":"2012","unstructured":"Perola E, Herman L, Weiss J (2012) Development of a rule-based method for the assessment of protein druggability. JCIM 52:1027\u20131038","journal-title":"JCIM"},{"issue":"9","key":"9994_CR7","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1021\/acs.jmedchem.5b01875","volume":"59","author":"B Kuhn","year":"2016","unstructured":"Kuhn B, Guba W, Hert J, Banner D, Bissantz C, Ceccarelli S, Haap W, Matthias Korner, Kuglstatter A, Lerner C, Mattei P, Neidhart W, Pinard E, Rudolph M, Schulz-Gasch T, Woltering T, Stahl M (2016) A Real-World Perspective on Molecular Design. J Med Chem 59(9):4087\u20134102","journal-title":"J Med Chem"},{"issue":"2","key":"9994_CR8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/jm00002a012","volume":"38","author":"MK Holloway","year":"1995","unstructured":"Holloway MK, Wai JM, Halgren TA, Fitzgerald PM, Vacca JP, Dorsey BD, Levin RB, Thompson WJ, Chen LJ (1995) A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. J Med Chem 38(2):305\u2013317","journal-title":"J Med Chem"},{"issue":"1","key":"9994_CR9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10822-014-9710-x","volume":"28","author":"G McGaughey","year":"2014","unstructured":"McGaughey G, Bayly C, Cox C, Schreier J, Breslin M, Bogusky M, Pitzenberger S, Ball R, Coleman P (2014) Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs. J Comput Aided Mol Des 28(1):5\u201312","journal-title":"J Comput Aided Mol Des"},{"issue":"14","key":"9994_CR10","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1021\/ja711120r","volume":"130","author":"N Liverton","year":"2008","unstructured":"Liverton N, Holloway MK, McCauley J, Rudd M, Butcher J, Carroll S, DiMuzio J, Fandozzi C, Gilbert K, Mao S, McIntyre C, Nguyen K, Romano J, Stahlhut M, Wan B, Olsen D, Vacca J (2008) Molecular modeling based approach to Potent P2-P4 macrocyclic inhibitors of hepatitis C NS3\/4A protease. JACS 130(14):4607\u20134609","journal-title":"JACS"},{"key":"9994_CR11","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1021\/jm401992e","volume":"57","author":"T Biftu","year":"2014","unstructured":"Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe J, Scapin G, Gao Y, Yan Y, Krueger D, Bak A, Eiermann G, He J, Cox J, Hicks Jacqueline, Lyons Kathy, He Huaibing, Salituro Gino, Tong Sharon, Patel Sangita, Doss George, Petrov Aleksandr, Joseph Wu, Shiyao Sherrie Xu, Sewall Charles, Zhang Xiaoping, Zhang Bei, Thornberry Nancy A, Weber Ann E (2014) Omarigliptin (MK-3102): a novel long-acting DPP4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem 57:3205\u20133212","journal-title":"J Med Chem"},{"key":"9994_CR12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nsmb.3183","volume":"23","author":"J Yin","year":"2016","unstructured":"Yin J, Babaoglu K, Brautigam CA, Clark L, Shao Z, Scheuerman T, Harrell CM, Gotter AL, Roecker AJ, Winrow CJ, Renger JJ, Coleman P, Rosenbaum DM (2016) Structures of the human OX1 orexin receptor bound to selective and dual antagonists. Nat Struct Mol Biol 23:293\u2013299","journal-title":"Nat Struct Mol Biol"},{"key":"9994_CR13","volume-title":"Creativity, Inc.: overcoming the unseen forces that stand in the way of true inspiration","author":"E Catmull","year":"2014","unstructured":"Catmull E, Wallace A (2014) Creativity, Inc.: overcoming the unseen forces that stand in the way of true inspiration.\u00a0Random House, New York"},{"key":"9994_CR14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1574-1400(06)02008-1","volume":"2","author":"WP Walters","year":"2006","unstructured":"Walters WP, Goldman B (2006) Machine Learning in Computational Chemistry. Annu Rep Comput Chem 2:127\u2013140","journal-title":"Annu Rep Comput Chem"},{"key":"9994_CR15","unstructured":"Kearnes S, Goldman B, Pande V (2016) Modeling industrial ADMET data with multitask networks. J Comput Inf Model (in press)"},{"key":"9994_CR16","unstructured":"Conway D, Cain S (2013) Quiet: the power of introverts in a world that can\u2019t stop talking, Broadway Books. http:\/\/drewconway.com\/zia\/2013\/3\/26\/the-data-science-venn-diagram"},{"key":"9994_CR17","volume-title":"The new economics","author":"EW Deming","year":"2000","unstructured":"Deming EW (2000) The new economics, 2nd edn. The MIT Press, Cambridge","edition":"2"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-016-9994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10822-016-9994-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-016-9994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T00:43:08Z","timestamp":1498351388000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10822-016-9994-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,29]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["9994"],"URL":"https:\/\/doi.org\/10.1007\/s10822-016-9994-0","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"type":"print","value":"0920-654X"},{"type":"electronic","value":"1573-4951"}],"subject":[],"published":{"date-parts":[[2016,11,29]]}}}